The purpose of this study is to investigate the effectiveness and safety of the regimen including high dose rifampicin for individualized duration (3 months after Culture Conversion) for the treatment of drug-sensitive pulmonary tuberculosis.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
926
Division of Pulmonology and Critical Care Medicine, Department of Internal Medicine and Lung Institute of Medical Research Center, Seoul National University College of Medicine
Seoul, South Korea
Incidence of unfavorable treatment outcomes between two arms
Time frame: Within 18 months of randomization
Time to unfavorable treatment outcomes
Time frame: Within 18 months of randomization
Time to culture conversion on liquid media
Time frame: Censored at 2 months of treatment
Proportion of participants with treatment success
Time frame: At the end of treatment
Proportion of participants with relapse of same strain
Time frame: At the end of study
Time to relapse with same strain
Time frame: through study completion, 18months after randomization
Occurrence of AEs grade 3 and above
Time frame: through study completion, 18months after randomization
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
15-20mg/kg
10mg/kg